vs

Side-by-side financial comparison of AbbVie (ABBV) and Envista Holdings Corp (NVST). Click either name above to swap in a different company.

AbbVie is the larger business by last-quarter revenue ($16.6B vs $750.6M, roughly 22.1× Envista Holdings Corp). AbbVie runs the higher net margin — 10.9% vs 4.4%, a 6.5% gap on every dollar of revenue. On growth, Envista Holdings Corp posted the faster year-over-year revenue change (15.0% vs 10.0%). AbbVie produced more free cash flow last quarter ($4.9B vs $91.7M). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 9.7%).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Envista Forensics is a United States based company that provides forensic engineering and recovery solutions for the insurance, legal, and risk management industries in the United States and internationally. Originally LWG Consulting, Inc., The company rebranded itself as Envista Forensics in 2017.

ABBV vs NVST — Head-to-Head

Bigger by revenue
ABBV
ABBV
22.1× larger
ABBV
$16.6B
$750.6M
NVST
Growing faster (revenue YoY)
NVST
NVST
+4.9% gap
NVST
15.0%
10.0%
ABBV
Higher net margin
ABBV
ABBV
6.5% more per $
ABBV
10.9%
4.4%
NVST
More free cash flow
ABBV
ABBV
$4.8B more FCF
ABBV
$4.9B
$91.7M
NVST
Faster 2-yr revenue CAGR
ABBV
ABBV
Annualised
ABBV
16.2%
9.7%
NVST

Income Statement — Q4 2025 vs Q4 2025

Metric
ABBV
ABBV
NVST
NVST
Revenue
$16.6B
$750.6M
Net Profit
$1.8B
$32.9M
Gross Margin
72.6%
54.7%
Operating Margin
27.3%
9.8%
Net Margin
10.9%
4.4%
Revenue YoY
10.0%
15.0%
Net Profit YoY
8354.5%
2641.7%
EPS (diluted)
$1.02
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABBV
ABBV
NVST
NVST
Q4 25
$16.6B
$750.6M
Q3 25
$15.8B
$669.9M
Q2 25
$15.4B
$682.1M
Q1 25
$13.3B
$616.9M
Q4 24
$15.1B
$652.9M
Q3 24
$14.5B
$601.0M
Q2 24
$14.5B
$633.1M
Q1 24
$12.3B
$623.6M
Net Profit
ABBV
ABBV
NVST
NVST
Q4 25
$1.8B
$32.9M
Q3 25
$186.0M
$-30.3M
Q2 25
$938.0M
$26.4M
Q1 25
$1.3B
$18.0M
Q4 24
$-22.0M
$1.2M
Q3 24
$1.6B
$8.2M
Q2 24
$1.4B
$-1.2B
Q1 24
$1.4B
$23.6M
Gross Margin
ABBV
ABBV
NVST
NVST
Q4 25
72.6%
54.7%
Q3 25
66.4%
55.3%
Q2 25
71.8%
54.2%
Q1 25
70.0%
54.5%
Q4 24
70.9%
57.1%
Q3 24
70.9%
52.8%
Q2 24
70.9%
51.6%
Q1 24
66.7%
57.1%
Operating Margin
ABBV
ABBV
NVST
NVST
Q4 25
27.3%
9.8%
Q3 25
12.1%
8.6%
Q2 25
31.7%
6.8%
Q1 25
28.0%
6.3%
Q4 24
-9.9%
7.1%
Q3 24
26.5%
3.5%
Q2 24
27.6%
-182.2%
Q1 24
22.7%
7.7%
Net Margin
ABBV
ABBV
NVST
NVST
Q4 25
10.9%
4.4%
Q3 25
1.2%
-4.5%
Q2 25
6.1%
3.9%
Q1 25
9.6%
2.9%
Q4 24
-0.1%
0.2%
Q3 24
10.8%
1.4%
Q2 24
9.5%
-181.9%
Q1 24
11.1%
3.8%
EPS (diluted)
ABBV
ABBV
NVST
NVST
Q4 25
$1.02
$0.20
Q3 25
$0.10
$-0.18
Q2 25
$0.52
$0.16
Q1 25
$0.72
$0.10
Q4 24
$-0.03
$0.00
Q3 24
$0.88
$0.05
Q2 24
$0.77
$-6.69
Q1 24
$0.77
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABBV
ABBV
NVST
NVST
Cash + ST InvestmentsLiquidity on hand
$5.3B
$1.2B
Total DebtLower is stronger
$58.9B
$1.4B
Stockholders' EquityBook value
$-3.3B
$3.1B
Total Assets
$134.0B
$5.7B
Debt / EquityLower = less leverage
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABBV
ABBV
NVST
NVST
Q4 25
$5.3B
$1.2B
Q3 25
$5.7B
$1.1B
Q2 25
$6.5B
$1.1B
Q1 25
$5.2B
$1.1B
Q4 24
$5.6B
$1.1B
Q3 24
$7.3B
$991.3M
Q2 24
$13.2B
$1.0B
Q1 24
$18.1B
$948.5M
Total Debt
ABBV
ABBV
NVST
NVST
Q4 25
$58.9B
$1.4B
Q3 25
$63.0B
$1.4B
Q2 25
$63.0B
$1.4B
Q1 25
$64.5B
$1.4B
Q4 24
$60.3B
$1.4B
Q3 24
$58.5B
$1.4B
Q2 24
$58.0B
$1.5B
Q1 24
$63.8B
$1.5B
Stockholders' Equity
ABBV
ABBV
NVST
NVST
Q4 25
$-3.3B
$3.1B
Q3 25
$-2.6B
$3.1B
Q2 25
$-183.0M
$3.1B
Q1 25
$1.4B
$3.0B
Q4 24
$3.3B
$2.9B
Q3 24
$6.0B
$3.1B
Q2 24
$6.8B
$3.0B
Q1 24
$8.0B
$4.1B
Total Assets
ABBV
ABBV
NVST
NVST
Q4 25
$134.0B
$5.7B
Q3 25
$133.9B
$5.6B
Q2 25
$137.2B
$5.7B
Q1 25
$136.2B
$5.5B
Q4 24
$135.2B
$5.4B
Q3 24
$143.4B
$5.5B
Q2 24
$141.9B
$5.4B
Q1 24
$148.9B
$6.6B
Debt / Equity
ABBV
ABBV
NVST
NVST
Q4 25
0.47×
Q3 25
0.47×
Q2 25
0.46×
Q1 25
45.44×
0.47×
Q4 24
18.15×
0.48×
Q3 24
9.70×
0.46×
Q2 24
8.56×
0.51×
Q1 24
7.97×
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABBV
ABBV
NVST
NVST
Operating Cash FlowLast quarter
$5.2B
$108.0M
Free Cash FlowOCF − Capex
$4.9B
$91.7M
FCF MarginFCF / Revenue
29.4%
12.2%
Capex IntensityCapex / Revenue
2.0%
2.2%
Cash ConversionOCF / Net Profit
2.87×
3.28×
TTM Free Cash FlowTrailing 4 quarters
$17.8B
$230.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABBV
ABBV
NVST
NVST
Q4 25
$5.2B
$108.0M
Q3 25
$7.0B
$78.7M
Q2 25
$5.2B
$88.7M
Q1 25
$1.6B
$300.0K
Q4 24
$7.0B
$132.4M
Q3 24
$5.4B
$70.7M
Q2 24
$2.3B
$93.1M
Q1 24
$4.0B
$40.3M
Free Cash Flow
ABBV
ABBV
NVST
NVST
Q4 25
$4.9B
$91.7M
Q3 25
$6.6B
$67.9M
Q2 25
$4.9B
$76.4M
Q1 25
$1.4B
$-5.6M
Q4 24
$6.8B
$123.8M
Q3 24
$5.2B
$63.3M
Q2 24
$2.0B
$86.3M
Q1 24
$3.8B
$29.3M
FCF Margin
ABBV
ABBV
NVST
NVST
Q4 25
29.4%
12.2%
Q3 25
42.1%
10.1%
Q2 25
31.7%
11.2%
Q1 25
10.5%
-0.9%
Q4 24
44.7%
19.0%
Q3 24
35.9%
10.5%
Q2 24
14.0%
13.6%
Q1 24
31.3%
4.7%
Capex Intensity
ABBV
ABBV
NVST
NVST
Q4 25
2.0%
2.2%
Q3 25
2.4%
1.6%
Q2 25
1.7%
1.8%
Q1 25
1.8%
1.0%
Q4 24
1.9%
1.3%
Q3 24
1.7%
1.2%
Q2 24
1.7%
1.1%
Q1 24
1.6%
1.8%
Cash Conversion
ABBV
ABBV
NVST
NVST
Q4 25
2.87×
3.28×
Q3 25
37.76×
Q2 25
5.49×
3.36×
Q1 25
1.27×
0.02×
Q4 24
110.33×
Q3 24
3.49×
8.62×
Q2 24
1.66×
Q1 24
2.95×
1.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABBV
ABBV

Segment breakdown not available.

NVST
NVST

Other$375.8M50%
Specialty Productsand Technologies$188.4M25%
Equipmentand Consumables$186.4M25%

Related Comparisons